Research programme: sphingosine 1 phosphate 1 receptor agonists - Exelixis/Boehringer Ingelheim

Drug Profile

Research programme: sphingosine 1 phosphate 1 receptor agonists - Exelixis/Boehringer Ingelheim

Latest Information Update: 09 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim; Exelixis
  • Class
  • Mechanism of Action Sphingosine 1 phosphate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 22 Feb 2011 Early research is ongoing in US and Germany
  • 08 May 2009 Early research in Autoimmune disorders in Germany (unspecified route)
  • 08 May 2009 Early research in Autoimmune disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top